Loading clinical trials...
Loading clinical trials...
A Phase 3, Double-blind, Double-dummy, Randomized, Placebo And Active Controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Dyslipidemia Who Are Intolerant To Statins
Conditions
Interventions
Bococizumab (PF-04950615;RN316)
Atorvastatin
+2 more
Locations
40
United States
Creekside Endocrine Associates, PC
Denver, Colorado, United States
Bridgeport Hospital
Bridgeport, Connecticut, United States
Watson Clinic Center for Research, Inc. (for Drug Shipment only)
Lakeland, Florida, United States
Cardiovascular Research Center Of South Florida
Miami, Florida, United States
St. Johns Center for Clinical Research
Ponte Vedra, Florida, United States
Progressive Medical Research
Port Orange, Florida, United States
Start Date
June 1, 2014
Primary Completion Date
November 1, 2015
Completion Date
November 1, 2015
Last Updated
December 14, 2017
NCT06062394
NCT07230730
NCT07334834
NCT07311941
NCT06903897
NCT06055036
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions